Endovenous Laser

Endovenous Laser Ablation of Varicose Veins

In a traditional surgical approach, ligation and division of the saphenous trunk and all proximal tributaries is followed by stripping or by avulsion phlebectomy. The main truncal ligation requires a substantial incision at the groin crease. Stripping of the vein may require additional incisions at the knee or below the knee and is associated with a high incidence of haematomas and nerv injuries.

Obliteration of the vein by endovenous laser ablation (EVLA) is a procedure that is less invasive than surgery and has a lower complication rate. The procedure is well tolerated by patients and produces good cosmetic results. Excellent clinical results are observed and been published on our 2300 patients in the past 19 years, and the long-term effectiveness of EVLA has thus been many times proven.

Endovenous laser has been employed since 1998 and approved by the Food and Drug Administration (FDA) in 2001. It is performed without or light sedation under diluted tumescent anaesthesia . Probably the main reason for a higher success rate has to do with viewing the treated area though systematic use of ultrasound guidance and duplex scanning during the procedure.


EVLA works by means of thermal destruction of the venous tissues. Laser energy from an 980-nm diode laser is delivered to the desired location inside the vein by using a bare laser fibre. When the laser is fired, it deposits thermal energy in the blood and venous tissues, causing irreversible localized venous tissue damage. The laser is repeatedly fired as the laser fibre is gradually withdrawn along the course of the vein under ultrasound assistance until the entire vessel is treated. Although a hole may be created in the vessel wall where the laser beam makes contact with it, permanent ablation of the vein is caused by thermal injury to the entire circumference of the vessel.


EVLA is of value in the treatment of truncal varicose veins (eg, greater saphenous vein) in patients with saphenofemoral incompetence. This procedure is also effective in the treatment of large branch veins and other large tributaries. Laser introducer catheters can be passed along small and crooked veins, but they cannot always be passed along an extremely tortuous vein with ease. In such cases a foam sclerotherapy is performed in those non accessible veins.

For treatment of the greater saphenous vein and the saphenofemoral junction, ultrasonography is used to confirm and map all areas of reflux and to trace the path of the refluxing greater saphenous trunk from the saphenofemoral junction down the leg to the upper calf. An appropriate
entry point is selected just above the ankle at a point that permits cannulation of the vessel with a standard BD Venflon™ Pro Safety Shielded IV 17G x 1.77 in. (1.5 mm x 45 mm) White Catheter. The course of the vein, the saphenofemoral junction, and the anticipated entry point are marked on the skin with a permanent marker.

The leg is prepared and draped, and a superficial local anaesthetic agent is used to numb the site of cannulation. Ultrasonography is used to guide needle puncture of the vessel. The Seldinger
technique, guidewires, and introducer sheath are not used in order to minimise venous spasm.

A 600-mm sterile, bare-tipped laser fibre is measured and advanced through the Venflon™ until it protrudes 1-2 cm from the tip of the sheath. With ultrasonographic guidance, the laser fiber is slightly withdrawn until the tip can be clearly observed at the level of the subterminal valve of the saphenofemoral junction.

Under ultrasonographic guidance, a dilute local anaesthetic agent is injected into the tissues surrounding the greater saphenous vein within its fascial sheath. An anesthetic is injected along the entire course of the vein from the catheter insertion point to the saphenofemoral junction. In most patients, 60-120 mL of lidocaine 0.25% is sufficient to anaesthetise and compress the vessel. Delivering the anaesthetic in the correct interfascial location with a volume sufficient to compress the vein and dissect it away from other structures along its entire length is important. Some practitioners prefer a local anaesthetic with epinephrine, whereas others prefer not to use epinephrine. The procedure is quick and does not cause early postoperative pain; thus, no long-acting local anesthetic agents are needed.

Ultrasonography is used to reconfirm the position of the laser fibre. The laser fibre tip is placed at the level of the subterminal valve of the saphenofemoral junction. When the laser console is
switched on, a red aiming beam is visible through the skin at the level of the saphenofemoral junction.

The console is set to deliver 13 Watt per pulse in 2-second duration pulses. The laser firing is controlled by a foot pedal with automatic pulses at 0,10-second intervals.

Manual pressure is applied to achieve venous wall apposition around the laser fibre tip as the laser is fired. The laser fibre is pulled back approximately 2 mm; manual pressure is again applied, and the laser is fired again. This procedure is repeated along the entire length of the vessel to be treated. With pulses delivered once per 1/10 second at 3-mm intervals, an entire greater saphenous vein can be treated.

If the vein is small, the laser energy may be adjusted to a lower intensity after the laser fibre has been withdrawn 5 cm or more below the saphenofemoral junction. In veins smaller than 0.5 cm in
diameter, the laser energy can be reduced to 8 J per pulse, with no apparent change in the outcome.

When the red guiding light is 10 cm from the entry point, the laser fibre is withdrawn from the catheter, than a flush foam scleroinjection in performed. The fibre is than re-introduce, the Venflon
pulled-out and laser fired to the point of entry. Pressure is applied to the puncture site for a few minutes, the procedure is complete

Immediately after the procedure, ultrasonography shows a patent vessel that is in spasm through most or all of its length. Follow-up ultrasonography at 1 week demonstrates nearly 100% early
closure of vessels.


Compression is vitally important after any venous procedure. Compression can reduce the (theoretic) risk of venous thromboembolism in the treated and untreated leg, and it is also highly
effective in reducing postoperative bruising and tenderness.

Postoperative bruising can be significant after EVLA, but it is much less prominent when lidocaine with epinephrine is used as the local anaesthetic. Bruising may be completely absent in patients
who wear compression hose continuously during the first 2 weeks after treatment. Postoperative tenderness after day 3 has also been reported, and it may be related to the amount of intravascular coagulum in the closing vessel. Tenderness is usually not observed in patients who wear compression hose continuously during the first week after EVLA.

Immediately after the procedure, a class II compression stocking (ie, one with a gradient of 30-40 mm Hg) is applied to the treated leg. Panty hose–style stockings, with compression applied to both legs, are preferred because the risk that the stocking will slip or roll is less. The stockings are worn for at least 1 week; they are kept in place continuously for the first 72 hours, but they may be removed for showering thereafter. Bedrest and heavy lifting are forbidden, but normal activity is otherwise encouraged.

The patient is re-evaluated on postoperative day 14 at which time duplex ultrasonography should demonstrate a closed greater saphenous vein and no evidence of thrombus in the femoral, popliteal, or calf deep veins.

At 6 to 8 weeks, an examination should reveal clinical resolution of truncal varices, and an ultrasonographic evaluation should demonstrate a completely closed vessel and no remaining reflux. If any residual open segments or branch veins are noted, perform sclerotherapy under ultrasonographic guidance.


Worldwide experience with this procedure is extremely good in the past 19 years an no serious complications of the procedure have been reported to date. Despite the absence of reported complications thus far, no procedure is without risks. Risk is associated with procedural problems such as malpositioning of the laser fiber. Any venous ablation procedure can trigger venous thrombosis in a susceptible patient.


Regarding outcome one must realise that we trat one aspect but not the condition not zhe genetic tendency for varicose vein progression. Vein obliteration after laser treatment is about 914% at 2 years follow-up. Published results show a high early success rate with a low subsequent recurrence rate for as long as 18 months after treatment. Late results are comparable to those obtained with more invasive surgical techniques, and evidence regarding the long-term effectiveness of the procedure are comparable to vein stripping with less recurrence at sapheno-femoral (inguinal) level. Patient satisfaction with the procedure has been very high and has become the standard procedure in our hands.

Print this Endovenous Laser Ablation

Dieser Beitrag ist auch verfügbar auf: Deutsch